Pharmacyte Biotech, Inc. cash flow statement PMCB

Annual Quarterly

In Q1 of fiscal 2027, the quarter ended Jul 31, 2026, Pharmacyte Biotech, Inc. used $780,894 of cash from operations, up 60.8% from the same quarter a year earlier.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jul 31, 2026	Q1 FY2027 Jul 31, 2026	Q4 FY2026 Apr 30, 2026	Q3 FY2026 Jan 31, 2026	Q2 FY2026 Oct 31, 2025	Q1 FY2026 Jul 31, 2025	Q4 FY2025 Apr 30, 2025	Q3 FY2025 Jan 31, 2025	Q2 FY2025 Oct 31, 2024
Operating
Stock-based compensation	—	—	0	1 +125.7%	0 -49.2%	0 -72.8%	0	0 -49.3%	0
Operating cash flow	-4 +14.3%	-1 +60.8%	-1 -33.9%	-1 -54.3%	-1 +7.1%	-2 -434.2%	-1 -212.5%	-1 -187.9%	-1 +46.8%
Investing
Investing cash flow	—	—	0	5	-3	0 +100.0%	0	0 +100.0%	0
Financing
Stock buybacks	—	—	0 -100.0%	0 +78.5%	0 -100.0%	0 -100.0%	0 -85.4%	0 -44.4%	1 +750.9%
Financing cash flow	6 +143.7%	-0	-0 +1.0%	1 +113.8%	6 +157.8%	0 +100.0%	-0 +98.4%	-4 +43.9%	-11 -1534.6%
Change in cash
Effect of exchange rate	0 +658.6%	-0 -600.0%	0 +20.6%	0 +312.2%	-0 -724.6%	0 -32.8%	0 +240.9%	-0 -213.9%	0 +103.8%
Net change in cash	5 +123.4%	-1 +56.6%	-2 -28.9%	5 +206.8%	2 +118.9%	-2 +88.6%	-1 +89.0%	-4 +63.5%	-12 -853.3%
Shareholder returns
Returned to shareholders	—	—	0	0	0	0	0	0	1
Ratios
Cash conversion	—	—	—	-1.05x	—	—	-0.09x	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: PMCB (Nasdaq)
Fiscal year ends: April 30
Incorporated in: NV
Headquarters: Las Vegas, NV
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1157075
Former names: NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.